Abstract Number: 0925 • ACR Convergence 2024
Macrophages Produce Bone Anabolic Factors in Settings of Inflammation-Induced Bone Formation
Background/Purpose: Understanding the pathogenesis of inflammation-induced pathologic bone formation remains a significant challenge in spondyloarthritis patients. We thought to uncover the pivotal events driving the…Abstract Number: 0936 • ACR Convergence 2024
Schnurri-3 Inhibition Protects from NF-kB-induced Bone Loss in Inflammatory Arthritis
Background/Purpose: In rheumatoid arthritis (RA), production of TNF promotes osteoclast activity and inhibits osteoblasts (OBs) and bone healing. Schnurri-3 (SHN3) is a potent suppressor of…Abstract Number: 1429 • ACR Convergence 2024
Association of Bone Erosion and Microarchitecture with Disease Activity and Damage in Sjögren’s Disease
Background/Purpose: Sjögren's disease (SjD) is a chronic multisystem autoimmune condition characterized by sicca syndrome and inflammatory arthralgia, more common in women. Bone involvement can result…Abstract Number: 1710 • ACR Convergence 2024
Extl3 Involved in the Regulation of Endochondral Ossification in Axial SpA
Background/Purpose: Spondyloarthritis (SpA) is an inflammatory rheumatic disease characterized, in its axial form, by lesions affecting the spine and/or sacroiliac joints (SIJ). Severe forms of…Abstract Number: 2117 • ACR Convergence 2024
The Risk of Medication-related Osteonecrosis of the Jaw (MRONJ) in a Patient with Osteoporosis Treated with Antiresorptive Therapy and Undergoing Dental Care Is Negligible with a CTX Threshold Above 260
Background/Purpose: Although antiresorptive treatments, including bisphosphonates and denosumab, have demonstrated their efficacy in treating osteoporosis. However, osteonecrosis of the jaw has been reported as a…Abstract Number: 2131 • ACR Convergence 2024
Role of LECT2 in the Regulation of Bone Metabolism In Vitro and In Vivo
Background/Purpose: Leucocyte cell derived chemotaxin 2 (LECT2) is a hepatokine produced in liver cells, secreted into the circulation, and acts as a hormone throughout the…Abstract Number: 2133 • ACR Convergence 2024
Unveiling the Association Between Low-Density Lipoprotein Cholesterol Lowering and Fracture Risk Among Patients with Hyperlipidaemia in a Population-Based Cohort Study: The Lower, the Better
Background/Purpose: High low-density lipoprotein cholesterol (LDL-C) is a major risk factor for fracture; however, whether LDL-C lowering induced by statins is associated with decreased fracture…Abstract Number: 2134 • ACR Convergence 2024
PEX5 Acts as a Negative Regulator of RANKL-induced Osteoclastogenesis In Vitro and Inflammatory Calvarial Bone Destruction In Vivo
Background/Purpose: Peroxisomal biogenesis factor 5 (PEX5) is essential for regulating peroxisome function by recognizing and transporting peroxisome target sequence receptor substrate proteins to peroxisomes. PEX5…Abstract Number: 1139 • ACR Convergence 2023
From Skin to Bone Lesions: A Pioneer Study Unraveling the Underdiagnosis of SAPHO Syndrome in the Dominican Republic
Background/Purpose: SAPHO syndrome is a rare chronic inflammatory condition that affects the skin and osteoarticular structures. Despite being first described over 30 years ago, it…Abstract Number: 1794 • ACR Convergence 2023
The Role of the Deubiquitinase ZRANB1/TRABID in Inflammation and Bone Formation in Spondyloarthritis
Background/Purpose: Inflammation and new bone formation are important disease mediators in ankylosing spondylitis (AS). Recent studies in mice show that the deubiquitinase molecule TRABID epigenetically…Abstract Number: 2015 • ACR Convergence 2023
Synergistic Effect Between Denosumab and Immune Checkpoint Inhibitors : A Retrospective Study of 268 Patients with Bone Metastases
Background/Purpose: Bone is the third site of metastasis. Bone metastases are associated with poorer survival of patients and impaired quality of life with the occurrence…Abstract Number: 2016 • ACR Convergence 2023
Generation of a Human 3D in Vitro Bone Model That Mimics Glucocorticoid-induced Osteoporosis
Background/Purpose: Osteoporosis is a bone disease characterized by low bone mass and changes in bone architecture, leading to pain and reduced mobility in patients. Glucocorticoid-induced…Abstract Number: 2150 • ACR Convergence 2023
Novel Biologic IRL201805 Inhibits Osteoclastogenesis in Monocytic Cells from RA Patients
Background/Purpose: In Rheumatoid arthritis (RA), osteoclasts derived from CD14+ Monocytes are associated with a risk of progressive bone and joint destruction, which fundamentally impacts quality-of-life.…Abstract Number: 0846 • ACR Convergence 2023
Preosteoclast Plays a Pathogenic Role in Syndesmophyte Formation of Ankylosing Spondylitis Through the Secreted PDGFB – GRB2/ERK/RUNX2 Pathway
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease that mainly affects the sacroiliac joint and spine. However, the real mechanisms of immune cells acting…Abstract Number: L11 • ACR Convergence 2022
Romosozumab versus Denosumab in High-risk Patients with Glucocorticoid-induced Osteoporosis: A Pilot Randomized Controlled Trial
Background/Purpose: To compare the efficacy and safety of romozosumab (ROMO) and denosumab (DEN) in high-risk patients with glucocorticoid -induced osteoporosis (GIOP)Methods: Adult patients (≥18 years)…
